• RBM partnership to end malaria warns single interventions not silver bullets • HEWAN kicks as jab hasn’t been tested in Nigeria with highest burden of disease Stakeholders in the fight to end malaria by 2030, led by Roll Back Malaria (RBM) partnership, have commended the World Health Organisation (WHO) for approving and recommending the…
Stakeholders in the fight to end malaria by 2030, led by Roll Back Malaria (RBM) partnership, have commended the World Health Organisation (WHO) for approving and recommending the second ever malaria vaccine, R21/Matrix-M.
Results of clinical studies published yesterday, showed that vaccine-drug combination reduced clinical malaria episodes, including cases of severe malaria and deaths from malaria in young children by nearly two-thirds...
Despite having highest burden of the disease, Nigeria will not benefit from 18 million doses of first-ever malaria vaccine allocated to 12 African countries for 2023–2025 by Gavi, the Vaccine Alliance, United Nations Children’s Fund (UNICEF) and World Health Organisation (WHO).
Following successful pilots, 2023 will see countries start to prepare for rollout of the world’s first malaria mass vaccinations; however, long-term supply and affordability remain a challenge.
In reaction, perhaps, to Ghana’s approval of its second malaria vaccine, last week, Nigeria, yesterday, granted provisional approval for the first malaria vaccine in the country.
The Nigerian government has approved the use of R21/Matrix malaria vaccine developed by scientists at Oxford University. “The National Agency for Food and Drug Administration and Control (NAFDAC) in exercising its mandate as stipulated by its enabling law, NAFDAC Act CapN1, LFN 2004 is granting registration approval for R21 malaria vaccine,” Director-general of the National…
Ghana has approved the second malaria vaccine ever, paving way for the protection of more children aged five to 36 months.